drugset / Trial / NCT04106414
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
Phase 2
Active not recruiting
24 enrolled
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.
Timeline
- Start
- 2019-09-24
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LINRODOSTAT | Small molecule | 100 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |